UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19, 2016
Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)
| Delaware | 000-50679 | 77-0487658 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
149 Commonwealth Drive
Menlo Park, CA 94025
(Address of principal executive offices, with zip code)
(650) 327-3270
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 Submission of Matters to a Vote of Security Holders
On May 19, 2016, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect seven directors to hold office until our 2017 annual meeting of stockholders and until their successors are elected and qualified, and 2) to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
A total of 109,710,939 shares of Corcept common stock held by stockholders of record at the close of business on April 8, 2016 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 103,229,513. The voting on the two matters is set forth below:
Proposal 1 – Election of Directors. The following directors were elected to serve until our 2017 annual meeting of stockholders and until their successors are elected.
| Director: | For | Withheld | Broker Non- Votes |
|||||||||
| G. Leonard Baker, Jr. |
71,279,606 | 3,320,003 | 28,629,904 | |||||||||
| Joseph K. Belanoff, M.D. |
74,007,363 | 592,246 | 28,629,904 | |||||||||
| Daniel M. Bradbury |
57,529,377 | 17,070,232 | 28,629,904 | |||||||||
| Patrick G. Enright |
73,929,155 | 670,454 | 28,629,904 | |||||||||
| David L. Mahoney |
73,887,755 | 711,854 | 28,629,904 | |||||||||
| Daniel N. Swisher, Jr. |
59,574,984 | 15,024,625 | 28,629,904 | |||||||||
| James N. Wilson |
65,747,905 | 8,851,704 | 28,629,904 | |||||||||
Proposal 2 – To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
| For |
102,079,492 | |||
| Against |
1,142,934 | |||
| Abstain |
7,087 | |||
| Broker Non-Votes |
N/A |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CORCEPT THERAPEUTICS INCORPORATED | ||||||
| Date: May 19, 2016 | By: | /s/ G. Charles Robb | ||||
| G. Charles Robb | ||||||
| Chief Financial Officer and Secretary | ||||||